Sexual Health / legal status / Last reviewed 2026-04-04

Degarelix Legal Status: Approval, Research Use, and Regulatory Notes

FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals.

Read the full Degarelix guide Browse answer pages

Direct Answer

Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.

Evidence grade
Level A
Research status
FDA Approved
Category
Sexual Health
Best for
Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology

Legal and Regulatory Status

FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals.

Approval Stage

Degarelix is listed as FDA Approved. Approved uses, if any, are indication-specific and do not automatically apply to other claims.

Compliance Notes

Evidence Page

For the complete evidence review, see the main Degarelix guide linked below.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesTestosterone Suppression (Level A), Prostate Cancer Control (Level A), and Cardiovascular Events (Level B)
Primary citation count3
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Degarelix Legal Status: Approval, Research Use, and Regulatory Notes." Last reviewed 2026-04-04. https://examinepeptides.com/answers/degarelix-legal-status/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.